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Abstract
An improved detergent-free process has been developed to produce vaccine based on native outer membrane vesicles
(NOMV) against Neisseria meningitidis serogroup B. Performance was evaluated with the NonaMen vaccine concept, which
provides broad coverage based on nine distinct PorA antigens. Scalable aseptic equipment was implemented, replacing
undesirable steps like ultracentrifugation, inactivation with phenol, and the use of preservatives. The resulting process is
more consistent and gives a higher yield than published reference processes, enabling NOMV production at commercial
scale. Product quality met preliminary specifications for 9 consecutive batches, and an ongoing study confirmed real-time
stability up to 12 months after production. As the NOMV had low endotoxic activity and induced high bactericidal titres in
mice, they are expected to be safe and effective in humans. The production process is not limited to NonaMen and may be
applicable for other N. meningitidis serogroups and other gram-negative pathogens. The current results therefore facilitate
the late-stage development and clinical evaluation of NOMV vaccines.
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Introduction
Neisseria meningitidis is a human pathogen that causes acute
meningitis and septicemia with high fatality rates [1]. Outbreaks of
serogroup B meningococcal disease in Norway, New Zealand, and
Cuba were successfully controlled with outer membrane vesicle
(OMV) vaccines, which was a milestone for the application of
OMV in vaccinology [2,3,4,5]. The outer membrane porin A
protein (PorA) is the dominant protective antigen but varies
among strains [6,7]. Recombinant strains with multiple PorA
subtypes were developed to increase vaccine coverage, resulting in
a nonavalent OMV vaccine (NonaMen concept) with potential
coverage of 80% [8,9,10,11]. Coverage has also been increased by
complementing multiple PorAs with other antigens, like fHbp or
FetA [12,13,14]. In addition OMV improved the immunogenicity
of a vaccine with purified fHbp, NadA and NHBA protein, which
has been submitted for regulatory review in Europe [15,16,17].
The use of OMV-based vaccines therefore remains a promising
approach for the control of serogroup B meningococcal disease
[18].
The vaccine strains used in Norway, New Zealand, and Cuba
contained lipopolysaccharide (LPS) with strong endotoxic activity.
To remove most of the LPS, the production process required
extraction by deoxycholate, a detergent of animal origin
[19,20,21]. The resulting detergent-extracted OMV (DOMV)
tended to aggregate, and the deoxycholate was not fully removed
during purification [20,21,22]. These issues, together with a high
strain specificity of the immune response, have delayed the late-
phase development of broadly protective DOMV vaccines. Van
der Ley et al. attenuated LPS by introducing the lpxL1 mutation
rather than physically removing it with detergent [23]. As lpxL1-
LPS has low endotoxic activity, it enables the development
vaccines based on native OMV (NOMV) for use in humans [24].
NOMV are very similar to the natural vesicles released during
infection [25]. Vaccines based on NOMV therefore have several
advantages over those based on DOMV, including absence of
aggregation and a broader immunogenicity provided by protective
lipoproteins like fHbp [22,26,27,28].
NOMV vaccines against N. meningitidis gave promising results in
preclinical and clinical studies, but were either produced at small-
scale or required process steps that are undesirable at commercial
scale [22,29,30,31,32,33]. These steps include the use of growth
medium with undefined components of animal origin (casamino
acids), inactivation of bacteria with hazardous chemicals like
phenol, or the use of excessive mechanical force to release or
homogenize NOMV (e.g., blender, micro fluidizer). Other
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problems involve use of preservatives with toxic components (like
thiomersal) and use of ultracentrifugation, which limits production
scale and complicates handling. NOMV production for phase III
clinical trials and commercial use demands an efficient and
reliable process that fully meets present-day regulatory require-
ments. As such a process was unavailable for NOMV vaccines, a
novel process was developed. Performance was assessed with the
NonaMen concept, a vaccine with broad coverage based on
nonavalent PorA. Our results show that this new process provides
a robust production platform for the late-stage development and
clinical evaluation of NOMV vaccines.
Results
Process outline and specifications
The improved NOMV production process is outlined in
Figure 1. Product phases A to H describe the production of bulk
NOMV. The upstream process starts with thawing of a working
seedlot (phase A). After multiple passages of growth, the 40 L
production culture is harvested (phase B), and biomass is
concentrated with microfiltration (phase C). After a detergent-free
treatment using the chelating agent EDTA (ethylenediaminetet-
raacetic acid), biomass is removed with consecutive centrifugation
and filtration steps to obtain the pathogen-free, crude NOMV
(phase D), which are the input material for downstream
processing. Crude NOMV are concentrated and washed with
ultra(dia)filtration (phase E), and DNA is digested with nuclease
(phase F). The resulting NOMV are purified with gel filtration to
remove salts and digested DNA fragments and also to enable a
buffer change to storage buffer (phase G). After sterile filtration
(phase H), the bulk NOMV from strains with trivalent PorA can
be stored until they are combined as a nonavalent vaccine and
diluted to the appropriate dose concentration (phase I). The bulk
NOMV vaccines in this study were produced for use in preclinical
evaluation. As a starting point for process development, specifi-
cations were defined for processing aspects based on analysis of
three reference processes: one large-scale NOMV process [31] and
two large-scale DOMV processes [20,21]. Supplementary Table
S1 compares these references with the current process. Table 1
summarizes the solutions designed to meet the specifications and
their current status of implementation.
Bacterial strains
The three RL production strains (DrmpM–DlpxL1 mutant
strains; Supplementary Table S2) with different combinations of
PorA antigens were adapted to the production medium and stored
as frozen master and working seedlots. Quality Control testing
confirmed microbiological identity (N. meningitidis), bacterial
monoculture (no contaminating organisms), cell viability
(.105 cfu/mL), and PorA identity (trivalent). Seedlots were
produced, released, and stored according to GMP guidelines
and may therefore be used to produce vaccines for clinical
evaluation. Genetic stability of the RL production strains was
constant at all four time-points that were assessed: master seedlot
(N= 0 generations of growth), production harvest (N= 2961
generations), and two post-production time-points (N= 4362 and
N=6161 generations of growth, respectively). PorA identity
results matched the subtypes in Supplementary Table S2, as did
the LPS identity (galE-lpxL1-LPS). Gene disruptions of rmpM and
porB were confirmed with PCR (data not shown). Disruption of the
cps locus (siaA, siaD and galE genes) was confirmed at all time-
points by testing functionality of the erythromycin resistance gene
(eryR) used for disruption. Comparable tests confirmed kanamycin
and chloramphenicol resistance at all time-points, providing
supplementary confirmation of lpxL1 and rmpM disruption. These
results indicate that the RL production strains are genetically
stable for at least 30 generations of growth beyond the usual
production harvest, in the absence of selective antibiotics.
Upstream production process
The primary pre-culture was inoculated with a thawed working
seedlot, grown in a shake-flask to an OD590 of 1.460.2 and used to
inoculate the secondary pre-culture, which was grown in
bioreactors to an OD590 of 2.960.9. Inoculants were transferred
during the exponential growth phase. All cultures were grown on
chemically defined growth medium, without antifoam, and a
mechanical foam breaker was implemented for the production
bioreactor [34]. Production cultures started at an OD590 of
0.1260.02, at 40 L cultivation volume. Biomass growth was
monitored by measuring OD590 and expressed as biomass
Figure 1. Flow-chart for improved NOMV production. Process
performance is evaluated with the NonaMen concept, a nonavalent
PorA vaccine comprised of three trivalent RL production strains
(DrmpM–DlpxL1 mutant strains; Supplementary Table S2). Production
of trivalent bulk NOMV is depicted in phases A to H. The transition from
one phase to the next requires a specific unit operation (1 to 10). The
seedlot (A) is first expanded in shake flask and bioreactor pre-cultures,
then used to inoculate the production bioreactor. Harvested cells (B) are
concentrated with microfiltration (C), and vesicle release is stimulated
with a detergent-free buffer containing the chelating agent EDTA (D).
Cells are discarded, and the crude NOMV are concentrated with
ultrafiltration (E). Any residual DNA is digested with nuclease (F), and
the extract is purified with gel filtration chromatography. The non-
sterile bulk (G) is then sterilized by filtration to obtain the bulk NOMV
(H). The trivalent product can be stored for at least one year before
mixing as nonavalent vaccine and diluting to dose concentration (I).
doi:10.1371/journal.pone.0065157.g001
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concentration (1 OD590 unit corresponds to 0.32 g/L dry biomass
or 2.47 g/L wet biomass). In addition, oxygen consumption was
monitored on-line to determine the harvest point. The resulting
characteristics are shown in Figure 2. Biomass growth was highly
reproducible for all cultivations (n = 6; duplicates for each strain;
R2= 0.977). Cultivation profiles were aligned at the time-point of
maximal oxygen consumption, which represented the onset of the
stationary phase (t = 0). The production cultures were harvested
for further processing at 3.160.3 hours after onset of the
stationary phase, with a wet biomass yield of 23.862.2 g/L.
Harvest was concentrated 5–8 fold with microfiltration (scalable,
aseptic) and washed with 2.160.2 volumes Tris-HCl pH 8.6
buffer to adjust pH. This ensured a pH of 8.3–8.6. The EDTA
treatment was performed with optimal setpoints for ‘harvest’ and
‘pH’, which were previously identified as critical process param-
eters [35].
Downstream production process
In the NonaMen vaccine concept, PorA is the primary
protective antigen, and therefore a high PorA content is desired.
When NOMV from the trivalent RL strains are properly purified,
PorA content comprises more than 55% of total protein present in
the vesicles [22,35]. Figure 3A shows how PorA content evolves
through the phases of the downstream process. During phases D,
E and F, it was relatively low at an average of 2665% of total
protein. Gel filtration chromatography removed impurities effec-
tively and reproducibly, resulting in a final PorA content of
7167% at phases G and H. This was significantly higher than at
the previous phases (p,0.0001). Figure 3A also shows the PorA
recovery at various production phases. Initial PorA yield after
EDTA treatment of cells (phase D) was set at 100%, and recovery
at downstream phases (E to H) was expressed as percentages of the
initial yield. Losses were distributed evenly across phases E, F and
G (2268%, 2267%, and 2567% yield loss, respectively), resulting
in a good overall PorA recovery of 31610%. PorA recovery for
RL strain 3 was lower than for the other strains, resulting in
slightly elevated standard deviations. Notably, sterile filtration
(phase G to H) was performed with a recovery of 9666%,
indicating that the OMV passed the 0.2 mm filter without
detectable losses.
Process yield
Mean yield of the novel process was substantially higher than
the yield of large-scale reference processes, as illustrated in
Figure 3B. Reference 1 [31] is most comparable to the current
process, since they are both detergent-free, whereas references 2
[20] and 3 [21] use detergent-extraction (Supplementary Table
S1). The mean yield of three RL production strains was
40617 mg total protein per L reactor volume, which was 15-
fold higher than reference 1 (2.7 mg/L), 2-fold higher than
reference 2 (21.7 mg/L), and 9-fold higher than reference 3 (1.9–
7.4 mg/L). However, the individual RL strains varied: RL strain 3
had a yield of 1962 mg/L, which was considerably less than RL
strains 1 and 2 (5466 and 4867 mg/L, respectively). Figure 3B
therefore shows the individual RL yields rather than their average.
In addition, Figure 3B confirms a substantially higher PorA yield
for all RL strains (2–30 fold). According to the literature, yield of
reference 1 was based on 270 L reactor volume, 450 mL product
with 0.8 mg/mL total protein and PorA content of 50% (our
estimation); yield was multiplied by 2.03, because 49.3% (not
100%) of total biomass was processed. Reference 2 yield was based
on 15 L reactor volume; 13000 doses (25 mg total protein with
33% PorA). Reference 3 yield was based on 135 L reactor volume;
250 to 1000 mg total protein with 89% PorA.
Quality Control
The most important aspect of process performance is the
resulting product quality, in this case the quality of bulk NOMV
with trivalent PorA. Therefore, batches of bulk NOMV (n= 9;
three for each RL production strain) were characterized with
Quality Control tests according to GMP and European Pharma-
copoeia (EP) guidelines. The analyses confirmed that quality was
within preliminary specifications for all batches (Table 2A). The
NOMV were sterile, had the expected PorA identity (trivalent),
Table 1. Specifications for improved NOMV production.
unit operation specification solution/result current status
1. produce biomass reproducible growth chemically defined growth medium optimized
scalable .500 L 40 L bioreactor, scalable to 800 L optimized [34]
no antifoam low-shear foam breaker optimized [34]
on-line harvest point decision oxygen consumption monitoring optimized
2. concentrate biomass replace centrifugation hollow fibre microfiltration functional [35]
3. increase OMV release mild, low-shear blender omitted functional
high extraction efficiency critical process parameters identified optimized [35]
aseptic biomass removal continuous centrifugation not functional
inactivation without phenol depth filtration 0.5–0.2 mm optimized
4. increase concentration replace ultracentrifugation ultrafiltration 100 kD cutoff functional
5. remove DNA replace ultracentrifugation nuclease treatment functional
6. remove impurities replace ultracentrifugation gel filtration chromatography optimized
7. sterilize replace thiomersal sterile filtration 0.2 mm optimized
high efficiency detergent-free (prevents aggregation) optimized [35]
An outline with 7 consecutive unit operations (corresponding to Figure 1) was used as a starting point for process development and optimization. One large-scale
NOMV process [31] and two large-scale DOMV processes [20,21] were used as references to define desired specifications for each unit operation (Supplementary Table
S1). Solutions that are expected to provide these specifications are summarized, together with their implementation status in the current production process.
doi:10.1371/journal.pone.0065157.t001
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high total protein content (1.460.2 mg/mL), high total PorA
content (0.9860.09 mg/mL), and low residual DNA
(0.00760.002 mg/mL). They also had native amounts of galE-
lpxL1-LPS (0.2360.06 mg/mL), homogeneous OMV size
(8167 nm), and absence of aggregation (363%). Three batches
of bulk NOMV (one for each trivalent RL strain) were assessed for
endotoxic activity, functional immunogenicity, stability, and
appearance (see paragraphs below). In addition, bulk NOMV
were mixed to produce nonavalent vaccine, for evaluation in mice
and rabbits. This separate study confimed that the nonavalent
vaccine induces broad immunogenicity and is well-tolerated [36].
The endotoxic activity of bulk NOMV (n= 3) was measured
with IL-6 monocyte activation (Table 2B). Used as references were
a DOMV vaccine with low toxicity, as proven in a phase I clinical
study [37], and a DTP-IPV vaccine (containing diphtheria and
tetanus toxoid, whole-cell pertussis, and inactivated polio virus).
The bulk NOMV induced 2762 ng/mL of IL-6 per human dose
(26, 27 and 29 ng/mL for RL strains 1, 2 and 3, respectively; one
human dose corresponded to 15 mg PorA of each PorA subtype).
This was approximately 25-fold lower than both reference
vaccines. The DOMV vaccine induced 700 ng/mL of IL-6 per
human dose, and the DTP-IPV vaccine induced 778 ng/mL of
IL-6 per human dose. Therefore the NOMV are expected to be
safe for parenteral use in humans.
Functional immunogenicity was assessed by measuring serum
bactericidal activity in mice sera after two immunizations with
trivalent bulk NOMV, one for each RL strain (Table 2C). High
bactericidal titres (.4 fold increase in mean 2log titre of
responders) were observed for 8 of 9 tested PorA subtypes. PorA
subtype P1.18-1,3,6 had a low titre, with only 1 mouse of 10
responding to vaccination. Of the 8 PorA subtypes with high titres,
P1.19,15-1 was just above threshold, and P1.7-1,1 had a lower
number of responders (5 out of 10 mice). These results indicate
that the bulk NOMV induced high functional immunogenicity in
mice for most PorA antigens.
In addition to the Quality Control tests, we assessed protein
composition and appearance of the NOMV. Total protein
composition (determined by SDS gel electrophoresis) is shown in
Figure 4A, illustrating the major contribution of PorA protein
(42 kD; 7167% of total protein). Overall protein composition of
bulk NOMV was comparable among the three trivalent RL
production strains, resulting in nonavalent vaccine with an equally
comparable composition. Dynamic light scattering (DLS) was used
to visualize NOMV appearance (Figure 4B) and found non-
aggregation; homogeneous size distribution with averages of
86.2 nm (RL strain 1), 86.7 nm (RL strain 2), and 73.8 nm (RL
strain 3); and low polydispersity indices of 0.12, 0.08, and 0.11,
respectively. A representative electron micrograph of non-
adjuvated nonavalent vaccine after dilution to dose concentration
(Figure 4C) showed fully intact, non-aggregated vesicles with a size
between 40 and 100 nm.
NOMV stability
The production dates of three batches of bulk NOMV (one for
each RL strain) were used as starting points for an ongoing real-
time stability study. The bulk NOMV were stored at a total PorA
concentration of 1 mg/mL, at 4uC in the dark. Quality Control
tests focused on biochemical aspects (PorA content, OMV size,
aggregation, and pH), sterility, and epitope concentration (deter-
mined by quantitative Biacore assay with specific antibodies
against a PorA subtype, using one representative PorA selected for
each RL strain). Stability data at 0, 3, 6 and 12 months after
production are presented in Supplementary Table S3. The data
did not contain trends with significant non-zero slopes, indicating
that the NOMV were sterile and had a stable PorA content, vesicle
size, and pH. Aggregation was low at all time points (,5%), but
trend analysis could not be performed due to skewed distribution.
Epitope concentrations seemed constant, but sample size at t = 12
was still too small for reliable trend analysis. The table shows
results for all time-points up to t = 12, indicating that the bulk
NOMV were stable for at least one year after production.
Trivalent bulk NOMV were also mixed to produce nonavalent
vaccine [36]. Functional immunogenicity (SBA) of this vaccine in
mice will be monitored up to 36 months after production in a
second, real-time stability study (data not yet available).
Discussion
An efficient and consistent process for the detergent-free
production of NOMV vaccine against N. meningitidis (Figure 1)
has been developed. Compared to previously described processes,
Figure 2. Upstream process characteristics. A) The upstream
process is performed at 40 L scale, which is representative for large-
scale (800 L [34]). Biomass growth (black line) on chemically defined
production medium is highly reproducible (regression R2 = 0.977).
Cultivations from RL production strain 1, 2, and 3 are indicated by
squares, circles, and triangles (respectively). Duplicates for each strain
are indicated with open and closed symbols, giving a total of 6
cultivations. B) Oxygen consumption is monitored continuously.
Cultivations are aligned at the time-point of maximal oxygen
consumption (t = 0), which represents onset of the stationary phase.
Harvest point of the cultivations has previously been optimized at
t = 3 hours [35].
doi:10.1371/journal.pone.0065157.g002
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the new process offers important improvements that are likely to
enable production at commercial scale (Table 1; Supplementary
Table S1) [20,21,31]. Process performance was evaluated with the
NonaMen vaccine concept, which provides broad protection
against serogroup B meningococcal disease based on nine different
PorA antigens [10,11,38].
The upstream process uses production strains with multiple
recombinant antigens that are genetically stable in the absence of
selective antibiotics. The strains also have mutations in lpxL1 and
rmpM genes to attenuate LPS toxicity and improve yield [22,23]
(Supplementary Table S2). Without these genetic modifications,
the detergent-free approach would not be feasible. To prevent
hydrophobic interactions with the outer membrane, antifoam is
omitted from the growth medium. Instead, a mechanical foam
breaker was used that does not impose significant shear force or
lysis [34]. The resulting growth curves are highly reproducible
(Figure 2A) and with a higher biomass yield than large-scale
references [20,31]. Biomass yield can be further improved by
implementing a feed strategy, since onset of the stationary phase is
triggered by nutrient depletion rather than limitations in the
oxygen supply (data not shown). The production culture is
harvested after three hours of the stationary phase, and the
harvest point is detected online with oxygen consumption
monitoring (Figure 2B). Biomass density is constant during this
period, but the oxygen consumption does not stabilize. It is
therefore uncertain whether the stationary phase is a temporary
transition from exponential growth to death phase, or a truly
stationary phase in which metabolism remains at maintenance
levels for a prolonged period.
Harvested biomass is concentrated with scalable, aseptic
equipment, and NOMV release is stimulated with a detergent-
free EDTA buffer under optimized conditions [35]. The EDTA
treatment does not require a blender, which is likely to increase
lysis. Spent biomass is then separated from the crude NOMV with
consecutive centrifugation and depth-filtration. These steps
remove all pathogenic activity from the crude NOMV without
the need for hazardous chemicals like phenol. However, the
centrifugation still requires handling in a biohazard cabinet, with
risk of contamination, and limits the process scale to approxi-
mately 100 L cultivation volume. Therefore future improvements
will include the implementation of alternatives, like continuous
flow centrifugation for initial biomass removal, as demonstrated
for Bordetella pertussis and fragile mammalian cells [39,40].
During downstream processing (Figure 3A), the crude NOMV
are concentrated with ultrafiltration, and nuclease is added for
digestion of any DNA. Subsequent gel filtration chromatography
removes impurities and ensures a high final PorA content. These
steps replace ultracentrifugation, which is commonly used and
effective but limits the production scale. Ultracentifugation also
requires manual homogenization of multiple NOMV pellets. This
is performed in a flow cabinet, with risk of contamination, and
followed by a microfluidizer treatment that imposes excessive
shear force. The current process uses scalable, aseptic equipment
and allows the NOMV to remain a stable colloid suspension
during all production stages. Overall PorA recovery is good,
approximately one third of the initial crude NOMV yield. The
ultrafiltration and nuclease steps give reproducible results but are
not yet optimized, resulting in higher losses and offering room for
future improvement. Importantly, sterile filtration of bulk NOMV
is performed without detectable losses and obviates the need for
preservatives like thiomersal. This is an notable benefit of the
detergent-free approach, ensuring that the NOMV are non-
aggregated and smaller than the filter cut-off (,220 nm).
Detergent-extracted OMV are prone to aggregation and more
Figure 3. Downstream process characteristics. A) PorA content and recovery are shown for the consecutive product phases of the downstream
process, from crude NOMV to bulk NOMV (Figure 1, phase D to H). PorA content (black bars) reaches final values from phase G onwards, indicating
that the gel filtration chromatography effectively removes impurities. PorA recovery relative to phase D (grey bars) shows that losses are spread
equally across the process, but notably not during sterile filtration (phase G to H), resulting in a reproducible and good overall recovery. Error bars
indicate standard deviation of combined data from the three RL production strains (n = 9). B) Total protein and PorA yield of RL bulk NOMV (phase H)
and large-scale reference processes. Reference 1 [31] is most comparable the current process since both are detergent-free (NOMV product).
References 2 [20] and 3 [21] use detergent-extraction (DOMV product). All RL strains have a higher PorA yield than the references. RL strain 3 has a
lower yield than the other two RL strains, resulting in a total protein yield that is comparable to reference 2 but still higher than the other references.
The results of individual RL strains are reprodicible, therefore this yield difference is not caused by the process. Error bars indicate standard deviation
of replicate batches (n = 3).
doi:10.1371/journal.pone.0065157.g003
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Table 2. Quality Control testing of bulk NOMV.
2A – general characteristics
QC parameter preliminary specification result (n = 9)
sterility no growth no growth
PorA identity trivalent trivalent
total protein .1.0 mg/mL* 1.460.2 mg/mL
total PorA 1.0060.25 mg/mL* 0.9860.09 mg/mL
PorA content .55% of total protein 7167%
galE-lpxL1-LPS 0.2560.15 mg/mL 0.2360.06 mg/mL
OMV size ,220 nm 8167 nm
aggregation no specification 363%
DNA ,0.050 mg/mL 0.00760.002 mg/mL
2B – endotoxic activity
vaccine preliminary specification result (ng/mL IL-6 per human dose)
bulk NOMV (n = 3) ,DTP-IPV reference 2762
DOMV (low toxicity) – 700
DTP-IPV reference – 778
2C – serum bactericidal activity
vaccine PorA subtype 2log titre** responders
bulk NOMV strain 1 (n = 1) P1.7,16 10.3 (.4) 9/10
P1.5-1,2-2 12.0 (.4) 10/10
P1.19,15-1 4.6 (.4) 9/10
bulk NOMV strain 2 (n = 1) P1.22,14 8.7 (.4) 10/10
P1.7-1,1 6.2 (.4) 5/10
P1.18-1,3,6 3.0 (,4) 1/10
bulk NOMV strain 3 (n = 1) P1.5-2,10 10.2 (.4) 10/10
P1.12-1,13 7.7 (.4) 10/10
P1.7-2,4 6.4 (.4) 7/10
A) General characteristics include biochemical composition, PorA identity, and sterility for which preliminary specifications were set. B) Endotoxic activity of the bulk
NOMV was approximately 25-fold lower than in DOMV and DTP-IPV reference vaccines. C) In addition, high bactericidal titres were induced in mice (2log titres .4 for 8
out of 9 PorA subtypes), with few non-responders. These results indicate that the bulk NOMV have a consistent product quality and are likely to be safe and
immunogenic in humans. *During processing PorA concentration of bulk NOMV is set at 1 mg/mL for storage purposes. **Mean titre of responders.
doi:10.1371/journal.pone.0065157.t002
Figure 4. Protein composition and appearance of NOMV. A) Protein composition of trivalent bulk NOMV is shown in lanes 1 to 3 for RL strains
1, 2 and 3, respectively (phase H), and composition of the nonavalent vaccine (phase I) in lane 4. Bulk NOMV from the three RL production strains are
comparable, therefore the nonavalent vaccine has an equally comparable protein composition. B) Vesicle size of trivalent bulk NOMV is similar for RL
strain 1 (black line), RL strain 2 (grey line), and RL strain 3 (dashed line). All bulk NOMV are non-aggregated and have comparable, homogeneous size
distributions, with averages between 74 and 87 nm. C) Electron micrograph of nonavalent vaccine (non-adjuvated) after dilution to dose
concentration shows that vaccine contains fully intact, non-aggregated OMV, an important benefit of the detergent-free production process.
doi:10.1371/journal.pone.0065157.g004
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heterogeneous in size, resulting in significant losses during sterile
filtration [21,22,41]. Even though these issues do not affect
immunogenicity, it is clearly beneficial to prevent them by
omitting the detergent-extraction [42].
Overall PorA yield of the new production process is substan-
tially higher than the yield of published reference processes with or
without detergent-extraction (Figure 3B) [20,21,31]. This is a
cumulative benefit of production strains with rmpM mutation [22],
a higher biomass yield, and a generally more efficient process. RL
strain 3 had a lower yield than the other strains but not as a result
of the process, which gave reproducible results for all three strains.
The lower yield may originate from a less effective assembly of
recombinant PorA antigens in strain 3, but this remains
speculative. One of the reference processes [20] was commercial-
ized to control a meningitis epidemic in New Zealand. Compared
to that reference, the current process shows a higher PorA yield for
all RL strains, avoids components of animal origin (deoxycholate),
and is scalable to at least 800 L cultivation volume [34]. Therefore
it is likely to be feasible at commercial scale.
Quality Control testing showed that product quality is within
preset criteria for all 9 bulk NOMV batches, an important
indicator for process performance (Table 2A). The product quality
has been constant for at least the first year of an ongoing real-time
stability study (Supplementary Table S3). This study seeks to show
stabililty for up to three years. Endotoxic activity of the bulk
NOMV is approximately 25-fold lower than a low-toxicity vaccine
based on detergent-extracted OMV [37] or the DTP-IPV vaccine
with whole-cell pertussis component. Long used in the Dutch
national vaccination program, that DTP-IPV vaccine had a
relatively high rate of adverse events and was replaced in 2005
with one containing acellular pertussis [43,44]. It thus represents
the upper range of low endotoxic activity, providing a useful
context for our results. Functional immunogenicity of the trivalent
bulk NOMV in mice is high, and comparable to detergent-
extracted HexaMen and NonaMen vaccine [10,21]. The im-
proved production process therefore generates high quality
NOMV that are likely to be well-tolerated and induce a functional
immune response in humans (Table 2B-C). The contribution of
individual PorA’s needs to be assessed in more detail, since
subtypes P1.7-1,1 and P1.18-1,3,6 gave low titres or few
responders. Other studies with multivalent PorA vaccine confirm
this observation [10,36]. Priming with monovalent OMV from less
immunogenic PorA subtypes before immunization with the
multivalent vaccine may solve this issue [45]. A recent study with
mice and rabbits confirmed that NonaMen vaccine from the
improved process induces broad immunogenicity without related
toxicity or pathology [36]. These results encourage clinical
evaluation.
The scope of the novel production process is not restricted to the
NonaMen concept and may be applicable for the late-stage
development of other NOMV vaccines. These include promising
serogroup B concepts with a different antigen composition or
vaccines against other N. meningitidis serogroups
[12,13,29,30,32,33,46]. The outer membrane vesicles from
gram-negative pathogens in general, like Escherichia coli, Vibrio
cholera, or Bordetella pertussis, are also within the scope if the
upstream process is adjusted to meet the nutritional requirements
of these pathogens [47,48,49,50,51,52,53]. Even recombinant
antigens derived from other pathogens may benefit from an OMV
presentation form [24,54,55,56]. This work thus provides a robust
production platform to facilitate the late-stage development and
clinical evaluation of NOMV vaccines.
Materials and Methods
Ethics statement
Animal experiments were performed at the Animal Care
Facility of the National Institute for Public Health and the
Environment (RIVM, The Netherlands), according to current
animal welfare regulations. The institutional Animal Ethical
Review Committee (DEC) of the National Institute for Public
Health and the Environment evaluated and approved the
experiments according to Dutch legislation (application number
DPA2011-00014). All efforts were made to minimize animal
suffering.
Trivalent strains and seedlots
The NOMV vaccines in this study were produced with RL
strains 1, 2 and 3 (Supplementary Table S2). Deletion of rmpM (R)
and lpxL1 (L) genes improved yield and attenuated LPS toxicity
[22]. The RL strains are non-encapsulated variants of the N.
meningitidis serogroup B isolate H44/76 [57] derived by deletion of
the cps-locus (siaA, siaD and galE genes). Each RL production strain
has 3 cloning sites for recombinant antigens, which were used to
express unique PorA subtype variants (NonaMen concept;
nonavalent PorA). For each strain, the research seedlot was
adapted to the production medium in Erlemeyer shake flasks to
obtain frozen master seedlots (Figure 1, phase A). One master
seedlot was used to generate approximately 50 frozen working
seedlots through two additional expansions in shake flasks (two-
tiered seedlot system). Master and working seedlots (cells at
OD590 = 1.560.3; stored at2135uC with 17% (v/v) glycerol) were
produced according to GMP guidelines.
Production of NOMV
Bulk NOMV were produced according to standard operating
procedures in a non-GMP pilot facility, but future use of the
process in a GMP facility was anticipated. Evaluation of
deviations, batch review, and batch release were performed by
QA/QP officers according to GMP standards. All cultures were
grown in chemically defined production medium free of animal
components and containing glucose, amino acids, salts, iron, and
trace elements [34]. A primary 150 mL pre-culture was inoculated
with 10 mL working seedlot and incubated in disposable 500 mL
shake flasks with vented closure (Nalgene, Rochester NY, U.S.A.)
at 35uC, 200 rpm. The pre-culture was used to inoculate a
secondary pre-culture, grown in a 5 L bioreactor with 3 L working
volume (Applikon, Schiedam, The Netherlands). At OD590 values
between 1.5 and 4.5, a fixed amount of bacteria (corresponding to
1 L at OD590 = 3) was transferred to the 60 L production
bioreactor with 40 L working volume (Applikon, Schiedam, The
Netherlands). Bioreactors were operated as described previously
[34]. Antifoam was omitted, and a mechanical foam breaker was
used to control foaming at 40 L scale (the 5 L reactor did not
require a foam breaker) [34]. The production culture was
harvested 3 hours after onset of the stationary phase (Figure 1,
phase B), as observed with online monitoring of the oxygen
consumption. Biomass was concentrated 5-fold using hollow-fiber
microfiltration units with 0.2 mm pore size and 1.8 m2 surface area
(Spectrum Laboratories, Rancho Dominguez CA, U.S.A). Circu-
lation was constant at 6.5 L/min, and feed pressure was
monitored (phase C). Concentrated biomass was then diafiltrated
with the microfiltration unit, using 2 volumes of buffer (100 mM
Tris-HCl, pH 8.6). Concentrated EDTA solution was added to a
final concentration of 10 mM to stimulate NOMV release (30 min
at ambient temperature with continuous stirring). Bacteria were
separated from the crude OMV by centrifugation (6 buckets with a
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content of max. 1 L; 75 min., 125006g, 4uC), and the supernatant
was depth-filtered (0.5–0.2 mm) to remove any residual pathogens
(phase D). In phase E, the crude OMV extract was concentrated
12-fold and washed with ultra(dia)filtration (100 kD cut-off;
100 mM Tris-HCl pH 8.6). In phase F, any DNA that might be
present was digested with 1000 U/L Benzonase (Merck; Schiphol-
Rijk; The Netherlands). To remove impurities (bacterial host
proteins, salts, small DNA), the NOMV were loaded onto a gel
filtration chromatography column packed with Sepharose 6 Fast
Flow size exclusion matrix (GE Healthcare, Hoevelaken, The
Netherlands). During gel filtration (phase G), the buffer was
changed to storage buffer containing 10 mM Tris-HCl pH 7.4
with 3% (w/v) sucrose [42]. Bulk NOMV were sterilized with
filtration (0.22 mm; Pall, Mijdrecht, The Netherlands), diluted to
storage concentration (1 mg total PorA/mL), and safely stored in
the dark at 2–8uC until further use (phase H). Stability of the bulk
NOMV under these conditions is at least one year (ongoing real-
time stability study). To prepare nonavalent vaccines for
preclinical evaluation purposes (phase I), aseptic fill and finish
were performed according to GMP guidelines. First, bulk NOMV
from three trivalent RL strains were mixed to achieve nonavalent
vaccine, then diluted to dose concentration with storage buffer,
based on PorA concentration. Vials with with 0.6 mL extractable
volume were filled with vaccine and labeled. Each vaccine dose
(0.5 mL) contained 15 mg of each PorA with a total of nine
different PorA subtypes (Supplementary Table S2).
Quality Control
QC tests were performed according to GMP and European
Pharmacopoeia guidelines. PorA identity was verified with
qualitative ELISA, using specific antibodies against each PorA
subtype [21]. OMV from monovalent PorA strains and a DporA
strain were used as controls. Total protein concentration (Ph.
Eur. 2.5.33) was measured with the Lowry protein assay.
Peterson’s modification was used to reduce the effect of interfering
substances [58]. The assay was performed according to manufac-
turer’s protocol (Sigma-Aldrich, Zwijndrecht, the Netherlands).
PorA content was determined by SDS gel electrophoresis (Ph. Eur.
2.2.31) followed by total protein staining and quantification of the
40–44 kD PorA bands. Gels were stained with Novex Colloidal
Blue (Invitrogen, Breda, The Netherlands), and PorA was
quantified as a percentage of total protein using TL100 1D gel
analysis software (Totallab, Newcastle upon Tyne, U.K.) [58,59].
Total nucleic acid concentration was used to estimate residual
genomic DNA. Samples were incubated with ethidium bromide
solution (MP Biochemicals, Illkirch, France), and fluorescence
intensity was measured to quantify DNA concentration based on a
salmon sperm DNA standard (Invitrogen, Breda, The Nether-
lands) [34,60]. For bulk NOMV and nonavalent vaccines, there
was no need to discriminate between RNA and DNA with an
RNAse pre-treatment, because total nucleic acid concentration
was low (,0.06 mg/mL). RNAse pre-treatment was used for in-
process controls on intermediate products (before phase F). Fatty
acid composition was analyzed to quantify LPS concentration
with a modified gas chromatography method [61,62] (Ph. Eur.
2.2.28). LPS was isolated with hot phenol-water extraction [63]
and quantified using the peak height of C14:0-3OH, with C12:0-
2OH as the internal standard (two C14:0-3OH residues per LPS).
The molecular weight of galE-lpxL1-LPS in the RL strains was
previously estimated at 2848 g/mol [22], but recent mass
spectrometry work provided a more reliable estimation of
3191 g/mol, which was used for this study (Pupo Escalona et al.,
manuscript in preparation). Identity of galE-lpxL1-LPS was
verified with mass spectrometry [64]. An aliquot of 200 mL
isolated LPS (see above; 50 nmol/ml) was freeze-dried and taken
up in 0.1 ml of 2% acetic acid (pH 2.8). The mixture was heated
to hydrolyze the LPS and release the lipid A moiety. Chloroform-
methanol (2:1 v/v) was used to extract the lipid A and, after phase
separation, the upper phase was used for analysis with mass
spectroscopy (nano electrospray tandem MS on a Finnigan LCQ
instrument in the negative-ion mode) [65]. Vesicle size
distribution was measured with dynamic light scattering (DLS)
at 25uC with a Malvern 4700 system [22] (Ph. Eur. 2.9.31). The
vesicle size distribution was reflected in the polydispersity index
(PdI), which ranges between 0.0 (fully homogeneous size
distribution) and 1.0 (random size distribution). Aggregation
was quantified by comparing the protein content of the NOMV
starting material with the protein content of the supernatant after
centrifugation at low speed (10 min. at 5000 xg) [22], using the
total protein assay described above. Aggregation was calculated by
expressing the difference between the total protein content of
supernatant and starting material as a percentage of the starting
material. Sterility was determined by filtration (Ph. Eur. 2.6.1).
Aliquots of 30 mL were filtered through a membrane (,0.45 mm
pore size) to retain any contaminating organisms and remove
constituents that might inhibit growth. The membrane was
incubated in shake flasks with 180 mL tryptic soy broth (TSB)
for 14 days at 30–35uC, with continuous aeration. The shake flask
was inspected for visible growth and, if negative or sterile, it was
inoculated with 10–100 cfu of B. subtilis and re-incubated as a
positive control for medium quality. Endotoxic activity of bulk
NOMV was measured as described previously by stimulating IL-6
production in human macrophage cell line MM6 [66] (Ph. Eur.
2.6.30) [22]. Macrophages were seeded in 96-well plates
(3.756104 cells/well) in 125 mL IMDM medium supplemented
with penicillin, streptomycin, L-glutamine, and fetal calf serum
(Invitrogen, Breda, The Netherlands). Two-fold dilution series
were made for all bulk NOMV samples in the supplemented
IMDM medium, and cells were stimulated by adding 125 mL to
each well. DOMV vaccine with known low toxicity (containing
reduced amounts of non-attenuated galE-LPS) [37] and DTP-IPV
vaccine (RIVM Bilthoven, The Netherlands) were included as
references. A human dose of DTP-IPV vaccine contained 4 IU
whole-cell pertussis, 30 IU diphtheria toxoid, 60 IU tetanus
toxoid, and 40, 4 and 7.5 D-antigen units of inactivated poliovirus
(type 1, 2 and 3, respectively). A human dose of OMV vaccine
corresponded to 15 mg of each PorA subtype. Cells were
stimulated for 16–18 hours at 37uC with 5% CO2, and IL-6 was
quantified in the supernatant using ELISA, according to
manufacturer’s protocol (PeliKine Compact, Amsterdam, The
Netherlands). Endotoxic activity was expressed in ng/mL IL-6 per
human dose. Serum bactericidal activity of trivalent bulk
NOMV was measured in sera of NIH mice (19–25 grams; ,8
weeks old) after two subcutaneous immunizations on day 0 and 14
with 22.5 mg PorA (7.5 mg of each PorA subtype), with 10 mice per
group. Sera were collected at day 28 and stored at 220uC.
Bactericidal titres were measured as described before [67]. PorA
epitope concentrations were quantified in bulk NOMV using
biosensor analysis on a Biacore T100 (GE Healthcare Benelux,
Diegem, Belgium). One representative PorA subtype was chosen
for each RL production strain: P1.7,16 for strain 1; P1.22,14 for
strain 2, and P1.12,13 for strain 3. Quantification was based on
titration of free antibody after incubation with bulk NOMV.
Recombinant PorA protein of a specific subtype was diluted in the
presence of 0.05% (w/v) Zwittergent 3.14 and subsequently
coupled to a CM5 sensor chip using an amine coupling kit
according to manufacturer’s protocol (GE Healthcare), with
immobilization levels between 10.000 and 12.000 response units
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(RU). Dilution series of bulk NOMV in HBS-P buffer (GE
Healthcare) were made, and samples were incubated overnight
with PorA-specific monoclonal antibody in a suitable dilution. An
OMV reference with known epitope concentration was also
included. After incubation, the mixtures were centrifuged (5 min.
at 30006g) to remove any aggregates. The antibody excess was
quantified by injecting samples on the sensor chip (10 ml/min for
two minutes). Assay data were analyzed by fitting a four-parameter
logistic curve with Biacore T100 evaluation software. PorA epitope
concentrations of bulk NOMV were calculated relative to the
reference OMV.
Strain stability
Genetic stability of the RL production strains was assessed by
continuing bacterial growth several generations beyond the
normal harvest point of the production culture, using shake flasks.
The age of the master seedlot was set at N= 0 generations, and
experimental seedlots were stored at N= 30 generations of growth
(regular production harvest), N= 45 generations (post-production
A), and N=60 generations (post-production B). The total number
of generations at each time-point was calculated by taking the
cumulative result of all previous passages in shake flasks and
bioreactors. The number of generations from an individual
passage was calculated with the formula: ln(DOD590)/ln(2), in
which DOD590 was the difference between the initial and final
OD590 of a passage. At each time-point, relevant genetic
modifications of the RL production strains (Supplementary Table
S2) were verified: PorA identity, identity of galE-lpxL1-LPS, rmpM
and porB gene disruptions. Resistance against erythromycin,
kanamycin, and chloramphenicol was tested by plating on GC
agar with these antibiotics.
NOMV stability
Stability of bulk NOMV was monitored in an ongoing three-
year stability study. The results up to 12 months after production
are currently available. Bulk NOMV (n= 3; one bulk product
from each RL strain) were stored at a total PorA concentration of
1 mg/mL, at 4uC in the dark. At t = 0, 3, 6 and 12 months, PorA
epitope concentration (one representative epitope for each bulk
product), PorA content, OMV size, aggregation, and pH were
tested as described above. Sterility was tested at t = 0 and t = 12
months after production. Results were assessed with trend analysis.
Data from replicates and time-points were merged for each
stability parameter and analyzed for normality and sufficient
sample size (D9Agostino’s K2 test; prerequisite for further analysis).
A trend line was fitted with linear regression, and trends were
tested for significant deviations from a non-zero slope (F test).
Supporting Information
Table S1 Comparison of large-scale OMV production
processes. The table shows how important OMV processing
aspects are addressed in the current production process and in
large-scale reference processes. Reference 1 [31] is most
comparable to the current process, since both are detergent-free.
References 2 [20] and 3 [21] use detergent-extraction. *The 40 L
bioreactor has been successfully scaled to 800 L [34]. **Will be
replaced with continuous centrifugation if scale-up to .100 L
cultivation volume is required.
(PDF)
Table S2 Genetic modifications of the trivalent RL
production strains. The RL strains are non-encapsulated
variants of strain H44/76, in which rmpM (R) and lpxL1 (L) genes
have been disrupted to improve yield and attenuate LPS toxicity
(galE truncated lpxL1-LPS). Each RL strain has 3 cloning sites for
recombinant antigens. The NonaMen vaccine concept (nonava-
lent PorA) is used to evaluate performance of the new production
process. Therefore all cloning sites of the trivalent RL strains
contain PorA subtype variants. The RL strains are genetically
stable for at least 30 generations of growth beyond the regular
production harvest, in the absence of selective antibiotics.
(PDF)
Table S3 Real-time stability of bulk NOMV. Results of an
ongoing stability study are shown at 0, 3, 6 and 12 months after
production. They are presented as A) Quality Control tests for
general stability aspects and B) Stability of selected PorA epitopes.
Results are highly reproducible throughout the study, as confirmed
by trend analysis, indicating that the bulk NOMV are stable for at
least one year after production. *P-value .0.05 indicates that the
time trend does not deviate significantly from a non-zero slope.
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